Jaguar health subsidiary napo pharmaceuticals submits late-breaking abstract for consideration for presentation at the 2021 idweek annual meeting

Exploratory study evaluating effects of crofelemer on gut microbiome san francisco, ca / accesswire / august 23, 2021 / napo pharmaceuticals, the wholly-owned subsidiary of jaguar health, inc. (nasdaq:jagx) today announced that an abstract associated with an exploratory clinical study on the effect of crofelemer (mytesi®) on the gastrointestinal microbiome in people living with hiv/aids (plwha) has been submitted for consideration for presentation at idweek 2021, which takes place virtually from september 29 to october 3. mytesi (crofelemer) is an antidiarrheal drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with hiv/aids on antiretroviral therapy (art).
JAGX Ratings Summary
JAGX Quant Ranking